EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Magnesium prophylaxis of new-onset atrial fibrillation: A systematic review and meta-analysis

Jeffrey Curran, Amanda Ross-White, Stephanie Sibley iD

PLOS ONE · 26.10.2023 · 18 (10) · e0292974

DOI: 10.1371/journal.pone.0292974 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 26.10.2023. Verfasst von Jeffrey Curran und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Queen's University, Kingston, Canada. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cardiac Surgical Procedures. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Atrial fibrillation (AF) is the most common cardiac arrhythmia in intensive care units (ICU) and is associated with increased morbidity and mortality. Magnesium prophylaxis has been shown to reduce incidence of AF in cardiac surgery patients, however, evidence outside this population is limited. The objective of this study is to summarize studies examining magnesium versus placebo in the prevention of NOAF outside the setting of cardiac surgery. Source We performed a comprehensive search of MEDLINE, EMBASE, and Cochrane Library (CENTRAL) from inception until January 3 rd , 2023. We included all interventional research studies that compared magnesium to placebo and excluded case reports and post cardiac surgery patients. We conducted meta-analysis using the inverse variance method with random effects modelling. Principal findings Of the 1493 studies imported for screening, 87 full texts were assessed for eligibility and six citations, representing five randomized controlled trials (n = 4713), were included in the review, with four studies (n = 4654) included in the pooled analysis. Administration of magnesium did not significantly reduce the incidence of NOAF compared to placebo (OR 0.72, [95% CI 0.48 to 1.09]).

Conclusion

Use of magnesium did not reduce the incidence of NOAF, however these studies represent diverse groups and are hindered by significant bias. Further studies are necessary to determine if there is benefit to magnesium prophylaxis for NOAF in non-cardiac surgery patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCardiac Surgical ProceduresHumansMagnesiumIncidenceMorbidity

Substanzen

Magnesium

Autor:innen und Institutionen

  • Department of Critical Care Medicine, Queen's University, Kingston, Canada.
  • Bracken Health Sciences Library, Queen's University, Kingston, Canada.

ORCID-Profile: Stephanie Sibley

Zitieren

APA

Curran, J., Ross-White, A., & Sibley, S. (2023). Magnesium prophylaxis of new-onset atrial fibrillation: A systematic review and meta-analysis. PLOS ONE, 18(10), e0292974. https://doi.org/10.1371/journal.pone.0292974

Vancouver

Curran J, Ross-White A, Sibley S. Magnesium prophylaxis of new-onset atrial fibrillation: A systematic review and meta-analysis. PLOS ONE. 2023;18(10):e0292974. doi:10.1371/journal.pone.0292974

BibTeX
@article{Curran2023,
  author = {Curran, Jeffrey and Ross-White, Amanda and Sibley, Stephanie},
  title = {Magnesium prophylaxis of new-onset atrial fibrillation: A systematic review and meta-analysis},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {10},
  pages = {e0292974},
  doi = {10.1371/journal.pone.0292974}
}
Kostenlos starten →